Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Edwin Fierer

Internal Medicine Bloomfield, CT Medical Doctor

NPI 1326062480 CMS profile 241173

580 Cottage Grove Rd, Suite 107, Bloomfield, CT 06002

Open in the dashboard

General payments

$2,823

172 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Edwin Fierer of Bloomfield, CT is reported in the CMS Open Payments database as having received $2,823 across 172 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $79 3
2022 General $18 1
2021 General $33 2
2020 General $373 20
2019 General $2,321 146

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edwin Fierer
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Edwin Fierer were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Edwin Fierer Internal Medicine median Middle half National median
2019 $2,321 $159 $48–$570 $163
2020 $373 $119 $33–$402 $114
2021 $33 $135 $37–$521 $132
2022 $18 $141 $42–$496 $149
2023 $79 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Novo Nordisk Inc $445 27 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $270 17 payments
  3. AstraZeneca Pharmaceuticals LP $260 15 payments
  4. Astellas Pharma US Inc $242 10 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $240 13 payments
  6. Pfizer Inc. $181 15 payments
  7. Sanofi-Aventis U.S. LLC $161 11 payments
  8. Amgen Inc. $137 7 payments
  9. Lilly USA, LLC $125 10 payments
  10. Janssen Pharmaceuticals, Inc $120 7 payments
  11. Other $642 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $2,725 169 payments
  2. Education $98 3 payments
Products named General payments · program years 2019–2023
  1. Ozempic $382 23 payments
  2. XIFAXAN $184 12 payments
  3. BEVESPI AEROSPHERE $149 7 payments
  4. CHANTIX $146 13 payments
  5. JARDIANCE $140 7 payments
  6. FARXIGA $138 6 payments
  7. Repatha $137 7 payments
  8. MYRBETRIQ $137 8 payments
  9. XARELTO $120 7 payments
  10. INVOKANA $120 7 payments
  11. Other $1,893 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

2,415

Median for Internal Medicine: 777

Drug cost

$367,226

Median for Internal Medicine: $73,373

Branded share of claims

19%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 78 $110,146
Ozempic Semaglutide Brand 28 $51,169
Trulicity Dulaglutide Brand 19 $48,245
Januvia Sitagliptin Phosphate Brand 25 $38,527
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 28 $29,210
Eliquis Apixaban Brand 24 $27,360
Farxiga Dapagliflozin Propanediol Brand 20 $24,950
Myrbetriq Mirabegron Brand 13 $9,584
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 17 $3,053
Synthroid Levothyroxine Sodium Brand 28 $2,252

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

172 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record